

ALEXION PHARMACEUTICALS INC  
Form 8-K  
November 30, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): November 29, 2011**

**ALEXION PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**000-27756**  
**(Commission**  
**file number)**

**13-3648318**  
**(IRS employer**  
**identification number)**

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

**352 Knotter Drive, Cheshire, Connecticut 06410**

**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code:**

**(203) 272-2596**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On November 29, 2011, Alexion Pharmaceuticals, Inc. issued a press release announcing that the European Commission has extended the therapeutic indication for Soliris® (eculizumab) to include the treatment of all pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on November 29, 2011 relating to the receipt of marketing authorization in the European Union for the treatment of aHUS.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALEXION PHARMACEUTICALS, INC.**

Dated: November 30, 2011

By: /s/ Michael V. Greco  
Name: Michael V. Greco  
Title: Associate General Counsel and Corporate Secretary

EXHIBIT LIST

- 99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on November 29, 2011 relating to the receipt of marketing authorization in the European Union for the treatment of aHUS.